Skip to main content
Download PDF

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

BMC Medicine volume 19, Article number: 190 (2021) Cite this article

Abstract

Background

Triple-negative breast cancer (TNBC) is a clinically aggressive disease with abundant variants that cause homologous recombination repair deficiency (HRD). Whether TNBC patients with HRD are sensitive to anthracycline, cyclophosphamide and taxane (ACT), and whether the combination of HRD and tumour immunity can improve the recognition of ACT responders are still unknown.

Methods

Data from 83 TNBC patients in The Cancer Genome Atlas (TCGA) was used as a discovery cohort to analyse the association between HRD and ACT chemotherapy benefits. The combined effects of HRD and immune activation on ACT chemotherapy were explored at both the genome and the transcriptome levels. Independent cohorts from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and Gene Expression Omnibus (GEO) were adopted to validate our findings.

Results

HRD was associated with a longer ACT chemotherapy failure-free interval (FFI) with a hazard ratio of 0.16 (P = 0.004) and improved patient prognosis (P = 0.0063). By analysing both HRD status and ACT response, we identified patients with a distinct TNBC subtype (ACT-S&HR-P) that showed higher tumour lymphocyte infiltration, IFN-γ activity and NK cell levels. Patients with ACT-S&HR-P had significantly elevated immune inhibitor levels and presented immune activation associated with the increased activities of both innate immune cells and adaptive immune cells, which suggested treatment with immune checkpoint blockade as an option for this subtype. Our analysis revealed that the combination of HRD and immune activation enhanced the efficiency of identifying responders to ACT chemotherapy (AUC = 0.91, P = 1.06e−04) and synergistically contributed to the clinical benefits of TNBC patients. A transcriptional HRD signature of ACT response-related prognostic factors was identified and independently validated to be significantly associated with improved survival in the GEO cohort (P = 0.0038) and the METABRIC dataset (P < 0.0001).

Conclusions

These findings highlight that HR deficiency prolongs FFI and predicts intensified responses in TNBC patients by combining HRD and immune activation, which provides a molecular basis for identifying ACT responders.

Peer Review reports

Background

Triple-negative breast cancer (TNBC) characterized by absent or minimal expression of oestrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) is a highly heterogeneous and aggressive disease and has the worst prognosis among the different subtypes of breast cancer [1, 2]. Among the chemotherapy regimens used for TNBC, sequential anthracycline (A) and cyclophosphamide (C) followed by taxane (T) (ACT) are some of the preferred regimens in international guidelines [3, 4]. However, approximately 30–40% of patients with residual disease (RD) after surgery treated with ACT-based therapy will develop metastatic disease and death [5].

The detailed molecular characterization of refractory tumours is a prerequisite to understanding therapy resistance and developing reasonable treatment strategies. Homologous recombination repair (HRR) is a high-fidelity repair mechanism specifically for DNA double-strand breaks (DSBs) [6]. BRCA1/2 are key components in the HR-mediated DNA DSB repair mechanism, and mutations in BRCA1/2 are typical molecular alterations that lead to homologous recombination repair deficiency (HRD) and sensitivity to DNA damage agents [7, 8]. In vitro and preclinical studies have shown that tumours with HR deficiency are sensitive to platinum-containing and/or DNA damage mutagens, which significantly increases the patient response rate and prolongs survival [9, 10]. However, whether HR deficiency could improve the response to DNA-damaging or repair-inhibiting therapies such as doxorubicin (which induces DNA DSBs) and cyclophosphamide (an alkylating agent that causes DNA crosslinks that lead to DSBs) [8, 10] in TNBCs remains poorly characterized, although BRCA1/2 germline mutations have been shown to promote the pathological complete response (pCR) in early TNBC patients who received ACT chemotherapy [11].

Among chemotherapy options in TNBC, combining immunomodulatory therapy (such as atezolizumab) with nab-paclitaxel and anthracycline-based chemotherapy is potentially advantageous, significantly improving pCR rates with an acceptable safety profile [12, 13]. Shibata et al. showed that the DNA DSB repair pathway upregulated the PD-L1 expression in cancer cells by activating STAT1 and STAT3 signalling and the IRF1 pathway [14]. Unrepaired DSBs regulate the tumour immune microenvironment through a series of molecular and cellular mechanisms, such as increasing genomic instability, activating immune pathway activation and facilitating PD-L1 expression on cancer cells, which might promote responsiveness to immune checkpoint inhibitors (ICIs) [15, 16]. The clinical and translational data indicated that low-dose chemotherapy may be utilized to stimulate anticancer immune responses. For example, short-term doxorubicin treatment may promote a more favourable tumour microenvironment and increase the likelihood of a response to PD-1 blockade in TNBC [17]. Additionally, low-dose cyclophosphamide induced antitumour T cell responses in metastatic colorectal cancer [18]. These studies indicated that it is necessary to consider the mechanism of the tumour immune microenvironment to characterize the effect of HRD on the ACT chemotherapy response.

Here, we performed an integrated genome analysis of TNBC patients who received ACT treatment after tumour resection, specifically focusing on HRD and the immune microenvironment and their combined effect on the treatment response and clinical outcomes. A transcriptional HRD signature as a prognostic factor related to ACT chemotherapy was identified and independently validated to be significantly associated with improved survival in the GEO cohorts and the METABRIC dataset. Our goal is to evaluate the combination of HRD and immune activation as a potentially stronger tool to predict which TNBC patients might achieve a valuable response to ACT-based preoperative chemotherapy.

Methods

Sample collection and datasets

Discovery cohort

In this study, we downloaded whole-exome sequencing (WES) data and gene expression profiles (RNA-Seq, RSEM standardization) for breast cancer patients in The Cancer Genome Atlas (TCGA) from cBioPortal [19]. Additionally, the patient survival and clinical phenotype (including age, PAM50 subtype and AJCC tumour stage) data were obtained. The sampling time points of patients and medication information related to the anticancer drugs used (including start/end time points of treatment) were obtained from the Genomic Data Commons Data Portal (GDC Data Portal). We reviewed the drug names and manually standardized them through DrugBank [20]. According to the dates given for sampling and first treatment, we obtained a clear cohort of primary breast cancer patients who received ACT treatments after tumour resection (Fig. 1). After determining the immunohistochemistry (IHC) status of ER, PR and HER2 and selecting patients for whom exome sequencing data were available, we established a final cohort of 83 TNBC patients (Table 1). Patients who were sensitive to ACT treatment were defined as having complete responses to ACT or a failure-free interval (FFI) above the median. Patients with disease progression or no improvement after ACT treatment ended (progressive disease/stable disease), or an FFI below the median were defined as resistant to ACT (Table 1).

Fig. 1
figure 1

Sampling procedure for TNBC patients prior to ACT chemotherapy

Full size image
Table 1 Patient and tumour characteristics of TNBC
Full size table

Validation cohorts

We downloaded data from GEO (GSE25055, GSE25065 and GSE41998), including expression profile, ACT response and clinical phenotype, for validation cohorts of TNBC patients who received neoadjuvant ACT therapy after sample procurement [21, 22]. A cohort of 299 TNBC patients who received ACT chemotherapy after tissue sample collection was obtained from METABRIC [23]. In addition, two cohorts of TNBC patients (Hess2006, neoadjuvant therapy; Chin2006, adjuvant therapies) who were treated with ACT after sample procurement were acquired from UCSC Xena [24, 25]. Hess2006 cohort patients undergoing diagnostic biopsy were prior to ACT neoadjuvant therapy. Information on all TNBC patients used in this study is provided in Additional file 1: Table S1.

HRD score, mutational signature and HRDetect score

The HRD score was calculated based on the number of specific lesions in the genome, including loss-of-heterozygosity (LOH), large-scale transitions (LST) and the number of telomeric allelic imbalances (ntAI). Following Thorsson et al.’s research on TCGA data [26], we extracted the HRD scores of TNBC patients. Somatic point mutational signatures were determined with the deconstructSigs R package [27] by using the COSMIC signatures as a mutational-process matrix. The WES-based HRDetect scores were calculated using the lasso logistic model by fitting multiple predictors related to HRD, including the HRD score, the contribution of major mutational signatures in breast cancers (such as signature 1, signature 3, signature 6 and signature 20) and the insertion/deletion ratio [28]. The weights of the whole exome–specific model were trained on 560 artificial whole exomes [29].

BRCA1 promoter methylation analysis

We acquired DNA methylation data (Illumina Human Methylation 450) from the UCSC Xena database. The transcription start site (TSS) information of the human reference genome (GRCh38) was obtained from Ensembl. The promoter region was defined as the 1500 bp upstream and 500 bp downstream of the TSS. We identified a robust probe (cg13782816) for the BRCA1 gene located in the promoter region through the gene symbol annotation information. BRCA1 promoter methylation (epigenetic silencing) was defined as a cg13782816 methylation level exceeding 0.9.

Immune microenvironment mechanism of TNBC patients

The R package CIBERSORT [30] was used to calculate the level of immune cell infiltration in TNBC patients. The IFN-γ score of the TNBC patients was calculated using the Tumor Immune Dysfunction and Exclusion (TIDE) online analysis tool [31]. The immune molecular and cellular characteristics of TCGA BRCA patients were obtained from a previous study [26], including tumour lymphocyte infiltration (TLI) score, regulatory macrophages (Mregs), TCR/BCR Shannon, TCR/BCR richness and TGF-β response and neoantigens. Tumour mutation burden (TMB) was defined as the total number of nonsynonymous single nucleotide and indel variants.

Gene set enrichment analysis and pathway activity calculation

We downloaded all the pathways of Collection 2 (C2) and their included gene sets from MSigDB (v7.2) [32]. Patients with the ACT-S&HR-P subtype served as the case group, other patients served as the control group and the R package DESeq2 was used for differential expression analysis. Gene set enrichment analysis (GSEA) was performed using the R package clusterProfiler. We acquired the gene sets of both immune cell types and core biological pathways from previous studies [33, 34] and calculated the activity of these pathways/immune cells utilizing the R package GSVA. We obtained sets of immunostimulators and immune inhibitors based on known studies [35, 36] and explored the differences in the expression of these genes between patients with ACT-S&HR-P and other TNBCs.

Immune score of TNBC patients

Two different methods were used to calculate the immune score (IS) of each TNBC patient based on the gene expression levels. (1) Due to the significantly higher activities of immune response-related pathways (including interferon and immune checkpoint blockade-related pathways, as well as CD8 effector T cells) in the ACT-S&HR-P subtype, we calculated the IS according to the sum of the activities of these pathways (Additional file 1: Table S2). (2). The IS was also calculated using the average expression of prognostic immune markers in breast cancer [37].

Identification of the HRD expression signature and computation of the HRD-related prognostic score

After grouping TNBC samples (HR deficiency and HR proficiency) according to HRD status and performing differential expression analysis using the R package DESeq2, we identified differentially expressed genes (DEGs) using FDR ≤ 0.05 and fold change ≥ 2 or ≤ 1/2 as the threshold. Univariate Cox regression analysis was performed in the FFI of TNBC patients based on the expression levels of all DEGs. Finally, 15 HRD-related prognostic factors (HRD expression signature) were determined after removing redundant factors using lasso logistic regression. Among those signature genes, 4 were strongly overexpressed (FDR ≤ 0.05, fold change ≥ 2), and 11 were downregulated (FDR ≤ 0.05, fold change ≤ 1/2) in HR-deficient compared to HR-proficient cases.

Considering the transcription levels of the HRD expression signature and the hazard ratio calculated by Cox regression analysis, the prognostic score (PS) of upregulated factors (all hazard ratio < 1, protective factor) and downregulated factors (all hazard ratio > 1, risk factor) were computed as follows:

$$ {\mathrm{PS}}_i\kern0.5em =\kern0.5em \sum \limits_{j=1}^n\frac{{\mathrm{Exp}}_{ij}}{{\mathrm{HR}}_j} $$

where HRj represents the hazard ratio of upregulated (or downregulated) factor j in the Cox model. Expij represents the expression levels (log-transformed) of upregulated (or downregulated) factor j in sample i. We calculated the HRD-related prognostic score (HRDPS) of patients based on the PS of both upregulated and downregulated factors as follows:

$$ {\mathrm{HRDPS}}_i\kern0.5em =\kern0.5em {\mathrm{PS}}_{i,\mathrm{up}}\kern0.5em -\kern0.5em {\mathrm{PS}}_{i,\mathrm{down}} $$

where PSi, up represents the prognostic score of upregulated factors in sample i, and PSi, down represents the prognostic score of downregulated factors in sample i.

Statistical analyses

R Project (version 4.02) for statistical computing was used in this study. The nonparametric Wilcoxon rank-sum test was used to explore the statistical significance between discrete variables (such as HRD status and ACT response status) and continuous indicators (such as immune cell infiltration and pathway activities). The nonparametric Kruskal-Wallis test was used for comparisons among multiple groups, with Benjamini and Hochberg false discovery rate (FDR) correction. For some comparisons (activated NK cells, M0 macrophages and activated mast cells), we additionally performed a combinatorial method that Wilcoxon’s rank-sum test with continuity correction combined 10,000 iterations. Fisher’s exact test was used to examine the relationships between HRD status and HRR-related gene mutations, BRCA1 promoter methylation and the effect on the response to ACT chemotherapy. Clinical outcomes and FFI were compared using the log-rank test. Kaplan-Meier graphs were plotted using standard methodologies. A Cox proportional hazards model was used to calculate the hazard ratios and corresponding 95% confidence intervals (CIs) with adjustments for age, tumour stage and disease stage. Statistical significance was set at two-tailed P < 0.05.

Results

Genomic alterations and homologous recombination repair defects were widespread in TNBC patients

We acquired data for 83 TNBC patients who underwent ACT chemotherapy after tissue sample collection based on the dates given for sampling and first treatment (Fig. 1). Consistent with a previous study [38], most TNBC patients belonged to the basal subtype (88%; Fig. 2A). As expected, TNBC patients carrying mutations in TP53 (84%), PTEN (11%) and BRCA1/2 (8% and 7%, respectively) were relatively frequent among breast cancer (BC) patients in the PanCancer Atlas [39] (Fig. 2A, Additional file 1: Fig. S1A). In contrast, the oncogene PIK3CA (11%) was less prone to the mutation in TNBCs than all BC patients.

Fig. 2
figure 2

Genome alterations and HRDs in TNBC patients. A Mutation profile of high-frequency mutation genes in patients (top 30). B Distribution of HRD score and mutational signature 3 activity in patients with HR deficiency and HR proficiency. The patients with BRCA1/BRCA2 mutations highlighted in blue and orange colours, respectively. C Box plot showing the distribution of mutational signature 3 exposure in patients with HR deficiency (HR-D) and HR proficiency (HR-P). SBS3, single-base substitution signature 3. P-value was calculated by the Wilcoxon rank-sum test. D, E The bar graph showing the relationship between HRD status and HRR gene mutation (D), BRCA1 promoter methylation/HRDetect score and HRDetect scorehi (≥ 0.7) (E). P-value was calculated by Fisher’s exact test

Full size image

Biomarkers for homologous recombination repair deficiency in cancers have attracted great interest from researchers [8, 40]. HR deficiency was defined as either a deleterious tumour BRCA1/2 (tBRCA) mutation or a predefined HRD score ≥ 42 [8], which was determined in 57.8% (48/83) of TNBC patients (Fig. 2A, Table 1). Our results showed that most TNBC patients with BRCA1/2 mutations presented HRD scoreshigh (≥ 42) and dominant mutational signature 3 (SBS3) activity (≥ 0.3) (both 8/11; Fig. 2B). Indeed, the patients with HR deficiency showed significantly higher SBS3 exposure than patients with HR proficiency (P = 4.3e−04, Wilcoxon rank-sum test; Fig. 2C). In addition to BRCA1/2, several important components of the HRR pathway, such as RAD54 family members (including RAD54B and RAD54L), DNA polymerase members (including POLD1, POLH and POLQ) and PARP1, PALB2 and TP53BP1, occurred mainly in the HR deficient samples (29/48, P = 3.04e−04, Fisher’s exact test; Fig. 2D, Additional file 1: Fig. S1B). Consistent with previous studies, we also found that HR-deficient patients showed a higher proportion of BRCA1 promoter methylation and HRDetect scorehigh (16/48, P = 0.018, Fisher’s exact test; Figs. 2A, E) [28, 41]. These results indicated that HRD could be characterized by mutations in HRR-related genes, SBS3 exposure and BRCA1 promoter hypermethylation.

Homologous recombination repair deficiency correlates with ACT chemotherapy benefits

Accumulated evidence has shown that HRD is associated with a better prognosis for patients with a variety of solid tumours [42, 43]. Whether a better prognosis is related to HRD in TNBC patients who received ACT chemotherapy has not been well characterized. Our results revealed that compared with patients with HR proficiency, patients with HR deficiency showed significantly better overall survival (OS; P = 0.0063, log-rank test; Fig. 3A) and disease-specific survival (DSS; P = 0.023, log-rank test; Additional file 1: Fig. S2A) after treatment with ACT. Specifically, the 5-year OS rate for HR-deficient patients was 98%, while that for HR-proficient patients, it was only 61% (Fig. 3A). Multivariate Cox regression analysis showed that HR deficiency was an independent protective factor associated with prolonged patient OS (P = 0.002, log-rank test; Additional file 1: Fig. S2B) and DSS (P = 0.014, log-rank test; Additional file 1: Fig. S2C) in TNBC after adjusting for clinical factors including age, AJCC stage and TNM stage.

Fig. 3
figure 3

Homologous recombination repair deficiency correlates with ACT chemotherapy benefits. A, C Kaplan-Meier graphs of HRD status on OS (A) and FFI (C). Statistical significance was calculated using the log-rank test. B Conceptual depiction of the TNBC patients undergoing ACT chemotherapy. D Forest plot illustrating the HR (95% CI) for FFI calculated using the multivariate Cox proportional hazard models. HR, hazard ratios; CI, confidence interval. E Distribution of ACT sensitive (light colour) or resistant (dark colour) in patients with HR deficiency (red) and HR proficiency (blue)

Full size image

Furthermore, to explore whether HR deficiency can indeed benefit TNBC patients’ response to ACT treatment, we determined the ACT chemotherapy failure-free interval (FFI) of patients based on the period from the end of treatment to tumour progression/recurrence or death (Fig. 3B). Our results showed that HR deficiency was correlated with durable response to ACT chemotherapy (P = 0.046, log-rank test; Fig. 3C). The 5-year FFI rate for HR-deficient patients was 75%, while that for HR proficiency, it was only 52%. Cox regression analysis showed that HR deficiency was a significant protective factor for FFI in TNBC patients with a hazard ratio of 0.16 (95% CI 0.044–0.55, P = 0.004; Fig. 3D), which improved the response interval to ACT chemotherapy. In addition, we found that HR-deficient patients tended to be more sensitive to ACT chemotherapy (54.2% for sensitive, 37.1% for resistant), compared with HR-proficient patients (37.1% for sensitive, 62.9% for resistant; P = 0.074, Fisher’s exact test; Fig. 3E).

Revealing the diversity of the immune microenvironment related to ACT responses utilizing HRD status

Unrepaired DNA damage, especially HRD, modulates the tumour immune microenvironment through a range of molecular and cellular mechanisms [15, 16]. Low-dose doxorubicin and cyclophosphamide chemotherapy may stimulate anticancer immune responses and promote a more favourable tumour microenvironment [17, 18]. We speculated that the impact of HRD on the immune microenvironment was related to the ACT response in TNBC patients. As expected, we found that the effect of HRD on immune cell infiltration showed significant differences in distinct ACT response groups (Fig. 4, Additional file 1: Fig. S3). For example, in the ACT-sensitive (ACT-S) group, NK cells showed higher infiltration in HR-proficient (HR-P) samples (P = 0.0079, Wilcoxon rank-sum test, same below; Fig. 4A). In contrast, M0 macrophages and mast cells presented higher infiltration levels in HR-deficient (HR-D) samples (P-values were 0.02 and 0.012, respectively; Additional file 1: Fig. S3AB). Interestingly, differences in these immune cells were not observed in the ACT-resistant (ACT-R) group (Fig. 4A, Additional file 1: Fig. S3AB). Additionally, in the ACT-sensitive group, we found that regulatory macrophages (Mregs) were significantly activated in HR-proficient patients (P = 0.0087, Wilcoxon rank-sum test; Fig. 4B). These patients showed T cell/B cell receptor (TCR/BCR) repertoire diversity (P-values of 0.041 and 0.019, respectively; Fig. 4C, Additional file 1: Fig. S3C) and TCR/BCR richness (P-values of 0.036 and 0.018, respectively; Additional file 1: Fig. S3DE). Diversified TCR/BCR receptors are the basic attributes of an effective immune system, allowing T/B cells to target multiple types of endogenous or exogenous antigens [44, 45]. However, we did not find corresponding results in the ACT-resistant patient group (Fig. 4C, Additional file 1: Fig. S3CDE).

Fig. 4
figure 4

Analysis of the immune microenvironment mechanism in TNBC patients. A–D The box diagram showing the distribution of activated NK cells (A) and the immune molecular and cellular characteristics, including regulatory macrophages (Mregs, B), BCR repertoire diversity (C) and tumour-infiltrating lymphocytes score (D). E, F Under different HRD status and distinct ACT responses, the patients with IFN-γ activity (E) and the expression of CTLA-4 (F) were diverse. P-value between the two (among multiple) groups was calculated by the Wilcoxon rank-sum (Kruskal-Wallis) test, the same below. ACT-S&HR-D: sensitive to ACT and HR deficiency (26 cases); ACT-S&HR-P: sensitive to ACT and HR proficiency (13 cases); ACT-R&HR-D: resistant to ACT and HR deficiency (22 cases); and ACT-R&HR-P: resistant to ACT and HR proficiency (22 cases). G–I The elevated expression of known cancer immunotherapy biomarkers, including CTLA-4 (G), PD-1 (H) and PD-L1 (I), were correlated with ACT-sensitive and HR proficiency (ACT-S&HR-P). The others mean all samples except ACT-S&HR-P

Full size image

Studies have suggested that neoantigens presentation in tumours promotes the release of IFN-γ from tumour-infiltrating lymphocytes (TILs), and the released IFN-γ upregulates PD-L1 expression in immune cells and tumours [46, 47]. We found that in the ACT-sensitive group, HR-proficient samples showed higher TIL infiltration (P = 0.0071, Wilcoxon rank-sum test, same below) and IFN-γ activity (P = 0.012) compared to HR-deficient samples (Fig. 4D, E). Among HR-proficient patients, those sensitive to ACT also showed higher TIL scores (P = 0.079, Wilcoxon rank-sum test, same below) and stronger IFN-γ activity (P = 0.009) than ACT-resistant patients (Fig. 4D, E). The patients with ACT-S&HR-P (sensitive to ACT and HR proficiency) were associated with higher IFN-γ activity (P = 0.011, Wilcoxon rank-sum test; Additional file 1: Fig. S4A) and lower TGF beta response (Additional file 1: Fig. S4B), implying an intense immune response in this subtype. Furthermore, for the known cancer immunotherapy biomarkers, we found that their expression levels were correlated with ACT response and HRD status (Fig. 4F, Additional file 1: Fig. S4CD). For example, significantly higher expression levels of CTLA-4, PD-1 and PD-L1 were found in ACT-S&HR-P patients (P < 0.05, Wilcoxon rank-sum test; Fig. 4G–I). In particular, patients with HR deficiency showed higher TMB (P = 0.0031, Wilcoxon rank-sum test; Additional file 1: Fig. S4E) and neoantigen levels (P = 0.0018, Wilcoxon rank-sum test; Additional file 1: Fig. S4F), which may be related to the fact that HRD exacerbates DNA DSBs, thereby promoting genome instability and causing the release of molecular antigens [48].

Immune checkpoint blockade as an optional treatment for patients with ACT-S&HR-P subtype

The clinical and translational data indicated that short-term doxorubicin treatment may increase the likelihood of a response to PD-1 blockade in TNBC [17]. Considering the results of our study, we postulated that ACT-S&HR-P patients may benefit from immune checkpoint blockade (ICB) therapy. To test this postulate, we performed GSEA on the C2 pathways from MSigDB (v7.2) (the “Methods” section). We found that the genes that were upregulated in ACT-S&HR-P patients were enriched in multiple immune response-related pathways, such as interferon-gamma signalling (NES = 2.53, FDR < 0.001; Fig. 5A, Additional file 1: Fig. S6A), interferon signalling (NES = 2.30, FDR < 0.001; Additional file 1: Fig. S5A) and type II interferon signalling IFN-γ (NES = 2.36, FDR < 0.001; Additional file 1: Fig. S5B). In addition, ICB-related pathways, including cancer immunotherapy by PD-L blockade (NES = 2.41, FDR < 0.001), the CTLA-4 pathway (NES = 2.55, FDR < 0.001) and CD28 family costimulation (NES = 2.45, FDR < 0.001), were related to the upregulated genes in this subtype (Fig. 5B, Additional file 1: Fig. S5CD). In particular, natural killer cell-mediated cytotoxicity (NES = 2.05, FDR < 0.001; Fig. 5C) and antigen processing and presentation (NES = 2.63, FDR < 0.001; Additional file 1: Fig. S5E) were also enriched to the upregulated genes in this subtype.

Fig. 5.
figure 5

Potential application of immune checkpoint blockade in the ACT-S&HR-P subtype. A–C Representative gene set enrichment analysis plot showing upregulated interferon gamma signalling (A), cancer immunotherapy by PD-L blockade (B) and natural killer cell–mediated cytotoxicity (C) in the ACT-S&HR-P (sensitive to ACT and HR proficiency) subtype versus the other subtypes. NES, normalized enrichment score. D Pathway activity in ACT-S&HR-P patients and other patients. The highlighted pathways are indicated as being focused on in this research. E In the ACT-sensitive group, immune cell activity scores were higher in the HR-proficient samples. The dots depict the mean difference of immune cell activity scores in HR-deficient samples compared to HR-proficient samples, and the lines show the 95% confidence interval (CI) for the difference. P < 0.05 was considered significant (red colour), Wilcoxon rank-sum test. See Figure S6 for the full name of immune cell types. F, G Relative number of immune-stimulatory cells (F) and immune-suppressive cells (G) in the four TNBC subtypes calculated using the CIBERSORT algorithm. H, I The expression of immune stimulatory molecules (H) and immune checkpoint genes (I) in four TNBC subtypes. ***P < 0.001, **P < 0.01, *P < 0.05

Full size image

Consistent results were found using pathway activity. For example, cancer immunotherapy by CTLA-4/PD-1 blockade was activated in ACT-S&HR-P patients (mean differences > 0, P < 0.05, Wilcoxon rank-sum test, the same below; Fig. 5D, Additional file 1: Fig. S6B). Similarly, the immune response-related pathways mentioned above also showed significant activation in this subtype, including interferon-gamma signalling (mean difference = 0.29, P = 0.0078), NK cell pathway (mean difference = 0.31, P = 0.011) and antigen processing and presentation (mean difference = 0.28, P = 0.0035) (Fig. 5D, Additional file 1: Fig. S6B). The JAK-STAT signalling pathway plays critical roles in the coordination of the immune system, especially for cytokine receptors, and it can regulate the polarization of helper T cells [14]. Our results showed that the genes upregulated in ACT-S&HR-P patients were enriched to the JAK-STAT signalling pathway (NES = 2.58, FDR < 0.001; Additional file 1: Fig. S5F). Additionally, the IL2-STAT4 pathway (NES = 2.62, FDR < 0.001) and IL2-STAT5 pathway (NES = 2.25, FDR < 0.001) showed correlations with the upregulated genes in this subtype (Additional file 1: Fig. S6A). Additionally, the pathways related to the inflammatory response, including the IL2-STAT4/5 pathways presented higher activities in this subtype (Fig. 5D, Additional file 1: Fig. S6B). These results suggested that ACT-S&HR-P patients exhibit surprisingly elevated immune activities by activating the immune response pathways.

By analysing the types of immune cells [33], we found that among HR-proficient patients, both innate immune cells (such as activated DCs [aDCs], mast cells, macrophages and natural killer (T) cells [NKs/MKTs]) and adaptive immune cells (such as T helper 1 [Th1], CD8+ T central memory [Tcm], CD8+ T effector memory [Tem] and CD4+ Tem cells) were activated only in the ACT-sensitive group (P < 0.05, Wilcoxon rank-sum test, the same below; Fig. 5E, Additional file 1: Fig. S6CD). Similarly, the core biological pathways, including immune checkpoint (P = 0.027), CD8 T effector (P = 0.011) and antigen processing machinery pathways (P = 0.027), were also activated in ACT-S&HR-P patients (Additional file 1: Fig. S6EF). Additionally, analysing both immune cell infiltration and differential expression profiling revealed that the ACT-S&HR-P subtype was enriched for both immune-activated cells and immunostimulators. For instance, immunostimulatory cells, such as M1 macrophages, NK cells and dendritic cells, showed significantly higher activity in ACT-S&HR-P patients (Fig. 5F). However, the number of immune-suppressive cells was not elevated in this subtype (Fig. 5G). Expression profiling demonstrated that immunostimulators such as CD40, CD86 and ICOS were significantly overexpressed in this subtype (Fig. 5H). The mechanisms by which ACT-S&HR-P patients show a stronger immune response likely involve the recruitment of immune-activated cells. In particular, our results revealed that immune inhibitors, especially IDO1, were significantly elevated in ACT-S&HR-P patients (Fig. 5I). This provides a valuable reference for additional reasonable immune checkpoint blockade therapeutics for TNBC patients with the ACT-S&HR-P subtype.

Enhanced efficacy of identifying ACT responders by combining HRD and immune activation

The above findings implied that HRD and immune cell activity might synergistically affect the ACT response; thus, we wondered whether the combination of HRD and immune activation could improve the ACT chemotherapy response. We computed the immune score (IS) of patients based on the immune response pathways (the “Methods” section) and annotated the patients with the highest 25% IS as being positive for IS (IS+). Our study showed that combined positivity (i.e. positivity for HRD, IS, or both) was significantly associated with clinical benefit (P = 1.9e−04, log-rank test; Fig. 6A) with a hazard ratio of 0.037 (95% CI 0.0048–0.29, P = 0.002, Additional file 1: Fig. S7C) and prolonged DSS of patients (P = 0.018, Additional file 1: Fig. S7AB). More importantly, we found that the patients with combined positivity had a longer ACT failure-free interval (P = 0.013, log-rank test; Fig. 6B). After adjusting for clinical factors, the combined positivity was found to be a significantly independent prognostic factor (HR = 0.21, 95% CI 0.064–0.67, P = 0.009; Fig. 6C). The results were consistent with the known prognostic immune markers of breast cancer (Additional file 1: Table S3, Fig. S7D-F). Incorporating IS into Cox models fit with age, tumour stage, and age and tumour stage improved the predictive accuracy of FFI (P < 0.002, likelihood ratio test; Fig. 6D), which highlights the importance of the combination of HRD status and immune activities in ACT chemotherapy. Additionally, we found that the prognostic efficacy of combined status (AUC = 0.91) was better than that of HRD status alone (AUC = 0.83) or clinical factors alone (AUC = 0.61) (Fig. 6E). These results indicated the necessity of combining HRD status with tumour immunity, which improves the efficacy of identifying ACT responders in TNBC.

Fig. 6
figure 6

Combining HRD and immune activation enhances the efficacy of identifying ACT responders. A, B OS (A) and FFI (B) by the status of combined HRD and immune activation. Log-rank test. C Multivariate Cox analysis after correcting for clinical factors such as age, AJCC stage and TNM stage. The pathology M stage is not included in the model due to incomplete information. ***P < 0.001, **P < 0.01, *P < 0.05. D The estimated likelihood ratio (LR) statistic of a Cox model in clinical factors, such as age, stage, and age and stage was compared. The change of LR statistic as features were added to the model was assessed for significance. E The area under the curve (AUC) of the combined status (orange colour), HRD status alone (green colour) and only clinical factors (grey colour) in the patient’s 5-year survival time (FFI) were compared

Full size image

To further validate those findings in an independent dataset of TNBC cases, we developed an HRD expression signature that predicts ACT response (FFI) in TCGA TNBC cohorts (the “Methods” section). We identified 15 genes that were associated with FFI, including 4 that had a better ACT response and 11 that had a worse response in HR deficiency than in HR-proficient cases (Fig. 7A, Additional file 1: Table S4). The HRD expression signature showed excellent performance in reflecting the genomic HRD status applied to TNBC patients, as demonstrated by a receiver operating characteristic (ROC) curve with an AUC of 0.89 (Fig. 7B), which was superior to other types of breast cancer samples, including all BC patients (AUC = 0.81) and BC patients except TNBC (AUC = 0.77).

Fig. 7
figure 7

Combined status contributes to ACT response and clinical prognosis of TNBC patients. A Hazard ratio of HRD expression signature was calculated using Cox regression model. Log (hazard ratio) > 0 indicates a risk factor (red); log (hazard ratio) < 0 indicates a protective factor (blue). B Performance evaluation that expression signature predicts HRD using lasso logistic regression in diverse types of breast cancer samples, including TNBC samples (green), breast cancer samples (red) and breast cancer except for TNBC (blue). C Distant relapse-free survival (DRFS) by combined status in GSE25065 TNBC cohort. D, E The bar chart shows the proportion of pCR/RD samples with the combined status in Hess et al. TNBC cohort (D) and GSE41998 TNBC cohort (E). pCR, pathological complete response; RD, residual disease. Neg, negative; Pos, positive. F OS by combined status in the METABRIC cohort. The prognostic of HRDPS alone was shown in Additional file 1: Fig. S8C. G The forest plot shows the combined status as an independent prognostic factor for TNBC patients using multivariate Cox regression analysis (METABRIC cohort)

Full size image

The combined score contributes to the ACT response and clinical benefit of TNBC patients

We demonstrated that the combination of the HRD-related prognostic score (HRDPS) and IS was an effective way to predict TNBC patients who may achieve pCR to ACT chemotherapy, showing better prognosis in independent validation sets (Additional file 2: Table S5) [21, 22, 24]. Our results indicated that the patients with combined positivity had longer distant relapse-free survival (DRFS; P = 3.8e−3, log-rank test; Fig. 7C). After adjusting for clinical factors, combined negativity was a significant independent risk prognostic factor in TNBC patients with a hazard ratio of 6.4 (95% CI 2.38–17.1, P < 0.001) compared to combined positivity (Additional file 1: Fig. S8A). However, there was no statistical significance when using HRDPS alone, although patients with HRD-positive had better DRFS (P = 0.062, log-rank test; Additional file 1: Fig. S8B). In addition, the patients with combined positivity had higher pCR rates of ACT in two independent validation sets (54.5% for Hess et al. TNBC, 44.4% for GSE1998 TNBC) compared with combined negativity cases (20% for Hess et al. TNBC, 26.9% for GSE1998 TNBC; Fig. 7D, E).

Furthermore, we analysed the impact of HRDPS, IS and combined status on the prognosis of TNBC patients who were treated with chemotherapy [23]. The results showed that the combination of HRD status and tumour immune activation showed a strong correlation with patient OS (P < 0.0001, log-rank test; Fig. 7F). The patients with positivity for both factors showed the longest OS compared with those with other statuses (P < 0.0001 compared with both negative, P = 0.001 compared with HRDPS-positive only and P = 0.012 compared with IS-positive only, log-rank test; Fig. 7F). Multivariate Cox regression showed that the patients who were negative for both (HR = 2.3 95% CI 1.26–3.9, P = 0.005) and HRDPS-positive only (HR = 2.3 95% CI 1.32–4.2, P = 0.004) showed a significantly worse prognosis compared with patients who were positive for both (Fig. 7G).

Similarly, we acquired consistent results in two additional validation sets of TNBC patients who received ACT intervention [22, 25]. For example, the patients with positivity for both HRDPS and IS showed the longest DRFS (GSE25055; P = 0.007 compared with IS-positive only; P = 0.041 compared with HRDPS-positive only; P = 0.053 compared with both negative, log-rank test; Additional file 1: Fig. S9A) and the best survival outcomes for DSS (Chin et al.; P = 0.037 compared with HRDPS-positive only; P = 0.049 compared with both negative, log-rank test; Additional file 1: Fig. S9B). These results demonstrated that the combination of HRD and tumour immune activation can indeed contribute to the ACT chemotherapy response and clinical outcomes of TNBC patients.

Discussion

In this study, we developed an integrated strategy to predict the ACT chemotherapy response through the combination of HR deficiency and immune activation in TNBC patients. Our method integrated multiomics data to ensure that we can not only characterize the HRD phenotype of TNBC using different methods but also analyse the effect on the ACT chemotherapy response in combination with the immune microenvironment. The presence of BRCA1/2 mutations or tumour genomic instability (HRD score ≥ 42) is surrogate markers of HR deficiency [8, 10], and a positive immune score is a surrogate of interferon-primed immune checkpoints in the tumour microenvironment [49]. The presence of one or both tumour features was associated with longer FFI (HR = 0.21, P = 0.009) and OS (HR = 0.037, P = 0.002) in TNBC patients. A transcriptional HRD signature related to the ACT response was independently validated to be significantly associated with improved survival in the GEO cohort (P = 0.0038) and the METABRIC dataset (P < 0.0001) and increased ACT pCR rates of TNBC patients. These results are clinically relevant and suggest that combining HRD status and tumour immunity may aid in the selection of TNBC patients who would benefit from ACT chemotherapy.

TNBC is a breast cancer subtype with fairly abundant defects in DNA damage repair, especially HRD (approximately 67%) [8, 10], which encourages us to start from the perspective of DNA DSBs and develop treatment strategies that are sensitive to DNA damage inducers or DNA synthesis inhibitors [9, 10]. Mutations in BRCA1/2 genes, especially germline variations, along with other Fanconi anaemia (FA) pathway genes (such as NBN, RAD54L, ATM), are prototypic molecular alterations that confer HRD in breast cancer [8]. Unfortunately, we cannot acquire information about germline BRCA1/2 variation from public data resources. The HRD score is an algorithmic assessment of three measures of tumour genomic instability, namely, loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions, which is a recognized indicator to characterize HRDs [10, 40]. BRCA1 promoter hypermethylation, as an inactivator of epigenetic modifications, was associated with a gene expression profile similar to that of inherited BRCA1 mutation-associated breast cancer [9, 41]. Mutational signature 3 is a genomic feature associated with failure of DNA DSB repair in breast cancer and is highly related to BRCA1/2 variation [41]. We identified HR-deficient patients with BRCA1/2 mutations or HRD scores ≥ 42 and indeed found that HR deficiency was associated with higher SBS3 activity, HRR gene mutations and BRCA1 promoter hypermethylation.

In agreement with previous observations, we found that HR deficiency was associated with better survival of TNBCs [8]. In addition, we further determined the FFI for TNBC patients who received ACT chemotherapy based on the period from the end of treatment to tumour progression/recurrence or death and found that HR deficiency was related to the patient durable response to ACT chemotherapy (P = 0.046). In cases of incomplete therapy response information from public databases, we explicitly classified TNBC patients as ACT-sensitive or ACT-resistant according to FFI and whether the tumour had progressed or complete responses after ACT treatment. This allowed us to further characterize the correlation between HRD status and ACT response. Considering the results of previous studies, the identification of TNBC patients who are sensitive to ACT is limited if only HRD status was considered [8]. The combined analysis of HRD status and the immune microenvironment provided us with an additional reference (Fig. 8), which made up for the limitations. Through transcriptional HRD signature analysis, we indicated that the HRD gene expression score was better at prognosis when combined with the immune score than their genetically determined HRD status. Our results demonstrated that the immunostimulatory cells and immune inhibitors (such as PD-L1, CTLA-4 and IDO1) were significantly elevated in ACT-S&HR-P patients, providing additional rationale for the use of immune checkpoint blockade as a therapeutic approach.

Fig. 8
figure 8

The characteristics summary of TNBC patients with HRD and ACT response. TMB, tumour mutation burden; ICIs, immune checkpoint inhibitors; TILs, tumour-infiltrating lymphocytes; NK cells, natural killer cells; TCR/BCR, T cell/B cell receptor; Tfh cells, T follicular helper cells

Full size image

The relative proportions of infiltrating immune cells were inferred based on gene expression profiles. However, mRNA only–based assessment of the immune infiltrate meets with several limitations. The architectural pattern and spatial distribution of TILs might be not captured by tumour transcriptomes. In addition, the differences of cellular RNA content may lead to estimation biases. And the calculation method particularly depends on the robustness of TIL marker genes [50, 51]. Therefore, it is necessary to consider the combination of immunohistochemistry to assess the immune infiltrate in future studies.

Conclusions

In summary, our findings highlighted that HR deficiency could prolong ACT chemotherapy benefits (failure-free interval) and predicted an intensified ACT response in TNBC patients by combining HRD and immune activation. The combination synergistically contributes to the clinical outcomes of TNBC patients and enhances the efficacy of identifying ACT chemotherapy responders, which resolves the issue that ACT chemotherapy-sensitive patients cannot be clearly identified using HRD status alone. The combined status of HRD and immune activation based on gene expression assay can be used as a potential prognostic marker for TNBC patients, which suggests that combining the two types of characteristics has important application value in guiding the use of ACT chemotherapy in TNBCs. This provides a molecular basis for accurately identifying ACT chemotherapy responders and has prospective significance in clinical trials.

Availability of data and materials

All of the data we used in this study were publicly available as described in the “Methods” section.

Abbreviations

ACT:

Anthracycline, cyclophosphamide and taxane

AUC:

Area under the curve

CIs:

Confidence intervals

DEGs:

Differentially expressed genes

DSBs:

Double-strand breaks

DSS:

Disease-specific survival

ER:

Oestrogen receptors

FDR:

False discovery rate

FFI:

Failure-free interval

GEO:

Gene Expression Omnibus

GSEA:

Gene set enrichment analysis

HER2:

Human epidermal growth factor receptor 2

HRD:

Homologous recombination repair deficiency

HRDPS:

HRD-related prognostic score

ICB:

Immune checkpoint blockade

ICIs:

Immune checkpoint inhibitors

IHC:

Immunohistochemistry

IS:

Immune score

LOH:

Loss of heterozygosity

LST:

Large-scale transitions

METABRIC:

Molecular Taxonomy of Breast Cancer International Consortium

ntAI:

Telomeric allelic imbalances

OS:

Overall survival

pCR:

Pathological complete response

PR:

Progesterone receptors

PS:

Prognostic score

RD:

Residual disease

ROC:

Receiver operating characteristic

TCGA:

The Cancer Genome Atlas

TLI:

Tumour lymphocyte infiltration

TMB:

Tumour mutation burden

TNBC:

Triple-negative breast cancer

TSS:

Transcription start site

WES:

Whole-exome sequencing

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.

    Article  PubMed  Google Scholar 

  2. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, et al. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018;4(3):302–8. https://doi.org/10.1001/jamaoncol.2017.4612.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18(4):452–78.

    Article  CAS  Google Scholar 

  5. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015;33(1):58–64.

    Article  PubMed  Google Scholar 

  6. Wright WD, Shah SS, Heyer WD. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018;293(27):10524–35. https://doi.org/10.1074/jbc.TM118.000372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44. https://doi.org/10.1016/S0140-6736(10)60892-6.

    Article  CAS  PubMed  Google Scholar 

  8. Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol. 2018;29(3):654–60.

    Article  CAS  PubMed  Google Scholar 

  9. Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110(7):704–13. https://doi.org/10.1093/jnci/djy085.

    Article  CAS  PubMed  Google Scholar 

  10. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pohl-Rescigno E, Hauke J, Loibl S, Mobus V, Denkert C, Fasching PA, et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020;6(5):744–8. https://doi.org/10.1001/jamaoncol.2020.0007.

    Article  PubMed  Google Scholar 

  12. Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100. https://doi.org/10.1016/S0140-6736(20)31953-X.

    Article  CAS  PubMed  Google Scholar 

  13. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17(3):345–56. https://doi.org/10.1016/S1470-2045(15)00542-2.

    Article  CAS  PubMed  Google Scholar 

  14. Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. https://doi.org/10.1038/s41467-017-01883-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78(24):6717–25. https://doi.org/10.1158/0008-5472.CAN-18-2652.

    Article  CAS  PubMed  Google Scholar 

  16. Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93. https://doi.org/10.1158/2159-8290.CD-17-0226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–8. https://doi.org/10.1038/s41591-019-0432-4.

    Article  CAS  PubMed  Google Scholar 

  18. Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res. 2017;23(22):6771–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018;33(4):690–705 e699. https://doi.org/10.1016/j.ccell.2018.03.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(Database issue):D901–6. https://doi.org/10.1093/nar/gkm958.

    Article  CAS  PubMed  Google Scholar 

  21. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873–81. https://doi.org/10.1001/jama.2011.593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res. 2013;19(6):1587–95.

    Article  CAS  PubMed  Google Scholar 

  23. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52. https://doi.org/10.1038/nature10983.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24(26):4236–44.

    Article  CAS  PubMed  Google Scholar 

  25. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529–41. https://doi.org/10.1016/j.ccr.2006.10.009.

    Article  CAS  PubMed  Google Scholar 

  26. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–30 e814. https://doi.org/10.1016/j.immuni.2018.03.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17(1):31. https://doi.org/10.1186/s13059-016-0893-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517–25. https://doi.org/10.1038/nm.4292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sztupinszki Z, Diossy M, Krzystanek M, Borcsok J, Pomerantz MM, Tisza V, et al. Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations. Clin Cancer Res. 2020;26(11):2673–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82. https://doi.org/10.1038/s41587-019-0114-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. https://doi.org/10.1186/s13059-017-1349-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8. https://doi.org/10.1038/nature25501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64. https://doi.org/10.1186/s13059-015-0620-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–40 e425. https://doi.org/10.1016/j.ccell.2019.02.001.

    Article  CAS  PubMed  Google Scholar 

  37. Yang B, Chou J, Tao Y, Wu D, Wu X, Li X, et al. An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer. 2018;4(1):35. https://doi.org/10.1038/s41523-018-0088-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hubalek M, Czech T, Muller H. Biological subtypes of triple-negative breast cancer. Breast Care. 2017;12(1):8–14. https://doi.org/10.1159/000455820.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291–304 e296. https://doi.org/10.1016/j.cell.2018.03.022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomarker Res. 2015;3(1):9. https://doi.org/10.1186/s40364-015-0033-4.

    Article  Google Scholar 

  41. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49(10):1476–86. https://doi.org/10.1038/ng.3934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reutersward C, Hakkinen J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526–33. https://doi.org/10.1038/s41591-019-0582-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239–54 e236. https://doi.org/10.1016/j.celrep.2018.03.076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12(9):669–77. https://doi.org/10.1038/nri3279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27(1):591–619. https://doi.org/10.1146/annurev.immunol.021908.132706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81. https://doi.org/10.1038/nature13988.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–6. https://doi.org/10.1038/nature14001.

    Article  CAS  PubMed  Google Scholar 

  48. Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Therapy. 2019;36(10):2638–78. https://doi.org/10.1007/s12325-019-01051-z.

    Article  Google Scholar 

  49. Farkkila A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(1):1459. https://doi.org/10.1038/s41467-020-15315-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Newman AM, Alizadeh AA. High-throughput genomic profiling of tumor-infiltrating leukocytes. Curr Opin Immunol. 2016;41:77–84. https://doi.org/10.1016/j.coi.2016.06.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Hackl H, Charoentong P, Finotello F, Trajanoski Z. Computational genomics tools for dissecting tumour-immune cell interactions. Nat Rev Genet. 2016;17(8):441–58. https://doi.org/10.1038/nrg.2016.67.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the staff members of TCGA Research Network, the cBioPortal, the GEO data, the UCSC Xena data portal and the CIBERSORT portal, as well as all the authors for making their valuable research data public.

Funding

This work was supported by the National Key R&D Program of China (Grant No. 2018YFC2000100), the National Natural Science Foundation of China (Grant No. 61873075, 32070673, 31871336), the Heilongjiang Provincial Natural Science Foundation (Grant No. YQ2019C012), the Heilongjiang Postdoctoral Foundation (Grant No. LBH-Q18099) and the Program for Young Scholars with Creative Talents in Heilongjiang Province (UNPYSCT-2017059).

Author information

Author notes

  1. Gaoming Liao, Zedong Jiang and Yiran Yang contributed equally to this work as first authors.

Authors and Affiliations

  1. College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, Heilongjiang, China

    Gaoming Liao, Zedong Jiang, Yiran Yang, Jiali Zhu, Liwen Xu, Aimin Xie, Min Yan, Yunpeng Zhang, Yun Xiao & Xia Li

  2. Department of Ultrasonic Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, 150010, Heilongjiang, China

    Cong Zhang

  3. Key Laboratory of University in Heilongjiang Province, Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China

    Meiting Jiang

  4. Key Laboratory of Cardiovascular Medicine Research, Harbin Medical University, Ministry of Education, Harbin, 150081, Heilongjiang, China

    Yun Xiao & Xia Li

Authors
  1. Gaoming Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zedong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiran Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meiting Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiali Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Liwen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aimin Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Min Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yunpeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yun Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: Liao. Acquisition, analysis or interpretation of the data: Liao and Jiang. Drafting of the manuscript: Liao, Jiang and Yang. Critical revision of the manuscript for important intellectual content: all authors. Study supervision: Li and Xiao. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yunpeng Zhang, Yun Xiao or Xia Li.

Ethics declarations

Ethics approval and consent to participate

This research has been conducted using publicly available datasets. De-identified data were used, and no ethical approval was required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

The mutations of homologous recombination repair genes in patients. Figure S2. Homologous recombination repair defects correlate with clinical benefits. Figure S3. Immune infiltration level of TNBC patients. Figure S4. Analysis of the immune microenvironment mechanism of TNBC patients. Figure S5. Representative gene set enrichment analysis plot. Figure S6. Immune checkpoints activated in the ACT-S&HR-P subtype. Figure S7. Combining HRD and immune checkpoints correlates with clinical benefits. Figure S8. HRD status and prognosis of TNBC patients. Figure S9. Combined status contributes to prognosis of TNBC patients. Table S1. Basic data information of TNBC patients. Table S2. Immune activation-related pathways and their genes. Table S3. Immune markers related to breast cancer. Table S4. Cox model results of HRD expression signature.

Additional file 2: Table S5.

The values for HRD score (transcriptional HRD signature) and immune score of TNBC patients.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liao, G., Jiang, Z., Yang, Y. et al. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer. BMC Med 19, 190 (2021). https://doi.org/10.1186/s12916-021-02068-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12916-021-02068-4

Keywords

  • Triple-negative breast cancer
  • ACT chemotherapy
  • Homologous recombination repair deficiency
  • Failure-free interval
  • Immune checkpoint

BMC Medicine

ISSN: 1741-7015

Contact us